Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HRS-1780 in primary aldosteronism
CTR20260921Phase 2Active
- Sponsor
- Shandong Sende
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-1780 in primary aldosteronism (PA), sponsored by Shandong Sende. Started Apr 2026; status: active.
02
Drugs
HRS-1780
03
Conditions
primary aldosteronism (PA)
Beyond the preview
Go deeper on CTR20260921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260921.